Furthermore, TAMs can facilitate cancer cell migration by activating EMT, for example upon release of lipocalin-2 (LCN2) [100], TNF-α [101], IL-8 [102,103], IL-6 [104], and TGF-β1 [105,106], which operate via activation of different EMT-promoting molecular pathways (e.g., Gas6/Axl-NF-κB, JAK2/STAT3/Snail, and PI3K/Akt). Here, AKT1 is linked to cancer.